PharmaShots Weekly Snapshot (Sept 07 -11, 2020)

 PharmaShots Weekly Snapshot (Sept 07 -11, 2020)

PharmaShots Weekly Snapshot (Sept 07 -11, 2020)

1. Janssen’s Tremfya (guselkumab) Receives the US FDA’s Approval as the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis

Published: Sept 10, 2020 | Tags:  Janssen, Tremfya, Guselkumab, Biologic, US FDA, Selective, IL-23 inhibitor, Active Psoriatic Arthritis, Severe Plaque Psoriasis, human mAb

2. Janssen Reports sBLA Submission to the US FDA for Darzalex Faspro (daratumumab and hyaluronidase-fihj) to Treat Patients with Light Chain (AL) Amyloidosis

Published: Sept 10, 2020 | Tags:  Janssen, Reports, sBLA, Submission, US, FDA,  Darzalex Faspro, daratumumab, hyaluronidase-fihj,  Treat, Patients, Light Chain, (AL), Amyloidosis

3. Chugai and Takeda Collaborate to Evaluate the Combination Therapy for Multiple Tumor Types in Japan

Published: Sept 10, 2020 | Tags: Chugai, Takeda, Collaborate, Evaluate, Combination Therapy, Multiple Tumor Types, Japan

4. GSK and Innoviva’s Trelegy Ellipta (FF/UMEC/VI) Receive the US FDA’s Approval for Asthma and COPD

Published: Sept 10, 2020 | Tags: GSK, Triple Therapy, Trelegy Ellipta, US FDA, Asthma, COPD, sNDA, Lung function, Acute Bronchospasm

5. Roche to Present New Data of Ocrevus (ocrelizumab) for Relapsing-Remitting Multiple Sclerosis at MSVirtual2020

Published: Sept 11, 2020 | Tags: Roche, Present, New Data, Ocrevus, (ocrelizumab), Relapsing-Remitting, Multiple Sclerosis, MSVirtual2020

6. Henlius Reports NMPA’s Acceptance of NDA for HLX04 (biosimilar, bevacizumab)

Published: Sept 10, 2020 | Tags: Henlius , Reports, NMPA,  Acceptance, NDA, HLX04, biosimilar, bevacizumab

7. Takeda Reports Results of Ninlaro (ixazomib) in a P-III Clinical Study for Newly Diagnosed Multiple Myeloma

Published: Sept 10, 2020 | Tags: Takeda, Reports, Results, Ninlaro, (ixazomib), P-III, Clinical Study, Newly Diagnosed, Multiple Myeloma

8. Jazz Collaborates with Redx Pharma to Develop Two Targeted Cancer Therapies

Published: Sept 09, 2020 | Tags: Jazz, Collaborates, Redx Pharma, Develop, Two, Targeted, Cancer Therapies

9. Genentech to Present New Data of Enspryng (satralizumab-mwge) for Neuromyelitis Optica Spectrum Disorder at MSVirtual2020

Published: Sept 10, 2020 | Tags:  Genentech, Present, New Data, Enspryng, (satralizumab-mwge), for Neuromyelitis Optica Spectrum Disorder, MSVirtual2020

10. Pfizer and BioNTech to Supply 200M Doses of it COVID-19 Vaccine in the EU

Published: Sept 09, 2020 | Tags:  Pfizer, BioNTech, Supply, 200M Doses, COVID-19 Vaccine, EU

11. AstraZeneca Reports Results of Fasenra (benralizumab) in P-III OSTRO Study for Chronic Rhinosinusitis with Nasal Polyps

Published: Sept 10, 2020 | Tags:  AstraZeneca, Reports, Results, Fasenra, (benralizumab), P-III, OSTRO Study, Chronic Rhinosinusitis with Nasal Polyps

12. Bayer Collaborates with Recursion to Fortify Digital Drug Discovery for Fibrotic Diseases

Published: Sept 09, 2020 | Tags: Bayer, Collaborates, Recursion, Fortify, Digital Drug Discovery, Fibrotic Diseases

13. Sanofi to Present New Data of its Neurology Portfolio at MSVirtual2020

Published: Sept 10, 2020 | Tags: Sanofi, Present, New Data, Neurology Portfolio, MSVirtual2020

14. Regenxbio Reports First Patients Dosing in its P-II AAVIATE Study of RGX-314 for Wet AMD

Published: Sept 09, 2020 | Tags: Regenxbio, Reports, First Patients Dosing, P-II, AAVIATE Study, RGX-314, Wet AMD

15. Merck Reports Results of Gefapixant (45mg) in Two P-III Studies for the Treatment of Refractory or Unexplained Chronic Cough

Published: Sept 08, 2020 | Tags: Merck, Reports, Results, Gefapixant, (45mg),  Two, P-III, Studies,  Treatment, Refractory, or Unexplained, Chronic Cough

16. Theranica’s Nerivio Wearable Device Receives CE Mark for Acute Treatment of Migraine in the Europe

Published: Sept 08, 2020 | Tags: Theranica, Nerivio, Wearable Device, CE mark, Acute Migraine, Chronic Migraine

17.  Takeda Divests its Select Non-Core Assets in EU and Canada to Cheplapharm for $562M

Published: Sept 09, 2020 | Tags: Takeda, Divests, its Select Non-Core Assets, EU, Canada, Cheplapharm, $562M

18.  Roche Expands its MS Portfolio with the Initiation of P-III Clinical Program of Fenebrutinib and Ocrevus (ocrelizumab)

Published: Sept 09, 2020 | Tags: Roche, Expands, MS Portfolio, Initiation, P-III, Clinical Program, Fenebrutinib, Ocrevus, (ocrelizumab)

19. Janssen’s Imbruvica (ibrutinib) + Rituximab Receives the EC’s Marketing Authorization for Previously Untreated Patients with Chronic Lymphocytic Leukemia

Published: Sept 08, 2020 | Tags: Janssen, Imbruvica, (ibrutinib), Receives, EC, Marketing Authorization, Approval, Chronic Lymphocytic Leukaemia

20. Silence Therapeutics Highlights its R&D Pipeline and Initiates Dose Escalation Studies for SLN360

Published: Sept 08, 2020 | Tags: Silence Therapeutics, Highlights, Pipeline Portfolio, Provides, Research, Development, Update

21. Roche’s cobas BKV Test Receives the US FDA’s 510 (k) Clearance to Improve Treatment for Transplant Patients

Published: Sept 08, 2020 | Tags: Roche, cobas BKV Test, Receives, US, FDA, 510 (k) Clearance, Transplant Patients

22. Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA TRAVERSE OLE Study for Asthma

Published: Sept 07, 2020 | Tags: Sanofi, Reports, Results, Dupixent, dupilumab, P-III, LIBERTY ASTHMA TRAVERSE OLE, Study, for Asthma

23. Mylan to Acquire Aspen’s Thrombosis Business in the EU for ~ $758M

Published: Sept 07, 2020 | Tags: Mylan, Acquire, Aspen, Thrombosis Business, EU, $758M

24. Boehringer Ingelheim and Pharmaxis Halt the Development of BI 1467335 for Diabetic Retinopathy

Published: Sept 08, 2020 | Tags: Boehringer Ingelheim, Pharmaxis, Halt, Development, BI 1467335, Diabetic Retinopathy

26. Project ALS’ Prosetin Receives the US FDA’s Orphan Drug Designation for Amyotrophic Lateral Sclerosis

Published: Sept 06, 2020 | Tags:  Project ALS, Prosetin, Receives, US, FDA, Orphan Drug Designation, Amyotrophic Lateral Sclerosis

27. Grifols to Acquire Remaining Stake of Alkahest for ~$146M

Published: Sept 06, 2020 | Tags: BMS, Acquire, Forbius, Adding, TGF-beta Inhibitor, Portfolio

28.  AstraZeneca to Present Results of Breztri Aerosphere in P-III ETHOS Study at ERS International Congress 2020

Published: Sept 07, 2020 | Tags: AstraZeneca, Present, Results, Breztri Aerosphere, P-III, ETHOS Study, ERS, International Congress 2020

29.Genentech’ Gavreto (pralsetinib) Receives the US FDA’s Approval Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Published: Sept 07, 2020 | Tags: Genentech, Gavreto, (pralsetinib), Receives, US, FDA, Approval, Metastatic, Rearranged, During, Transfection, Fusion-Positive, Non-Small Cell Lung Cancer, Adults

30. Kite Reports sBLA Submission to the US FDA for Yescarta (axicabtagene ciloleucel) in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas

Published: Sept 06, 2020 | Tags:  Kite, Reports, sBLA, Submission, US, FDA for Yescarta, axicabtagene ciloleucel, Relapsed, Refractory, Indolent Non-Hodgkin Lymphomas

31. Chi-Med Initiates P-III FRESCO-2 Study of Fruquintinib in Metastatic Colorectal Cancer

Published: Sept 06, 2020 | Tags: Chi-Med, Initiates, P-III, FRESCO-2 Study, Fruquintinib, Metastatic Colorectal Cancer

Related News: PharmaShots Weekly Snapshot (Aug 31 – Sept 04, 2020)

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post